Attached files
| file | filename |
|---|---|
| EX-99.2 - ABSTRACT - Cellular Biomedicine Group, Inc. | cbmg_992.htm |
| EX-99.1 - PRESS RELEASE - Cellular Biomedicine Group, Inc. | cbmg_991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): May 19,
2017
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36498
|
|
86-1032927
|
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
19925 Stevens Creek Blvd., Suite 100
Cupertino, California
|
|
95014
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (408)
973-7884
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 7.01 Regulation FD
Disclosure.
On May
19, 2017, Cellular Biomedicine Group, Inc. issued a press release
announcing that an abstract exploring the application of B-cell
antigen, CD20, for targeted Chimeric Antigen Receptor T cells
(CAR-T) therapy has been accepted for publication in conjunction
with the 2017 American Society of Clinical Oncology (ASCO) Annual
Meeting in Chicago to be held from June 2 to June 6, 2017. A copy
of the press release and the abstract is attached hereto as Exhibit
99.1 and Exhibit 99.2, respectively.
Item 9.01. Financial Statements and
Exhibits.
|
(d)
|
|
Exhibits
|
|
99.1
|
|
Press Release,
dated May 19, 2017
|
|
99.2
|
|
Abstract
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
|
|
|
Date:
May 19, 2017
|
By:
|
/s/ Bizuo
(Tony) Liu
|
|
|
|
|
Bizuo
(Tony) Liu
|
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
|